Medigene AG (MDG1.DE)
EUR 1.08
(-1.64%)
EUR 1.08
(-1.64%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.03 Million EUR | -25.86% |
| 2022 | 2.74 Million EUR | -12.44% |
| 2021 | 3.13 Million EUR | -21.44% |
| 2020 | 3.99 Million EUR | -6.86% |
| 2019 | 4.28 Million EUR | 418.26% |
| 2018 | 827 Thousand EUR | -21.16% |
| 2017 | 1.04 Million EUR | 209.44% |
| 2016 | 339 Thousand EUR | -38.14% |
| 2015 | 548 Thousand EUR | -94.83% |
| 2014 | 10.59 Million EUR | 2.33% |
| 2013 | 10.35 Million EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.61 Million EUR | 0.0% |
| 2024 Q1 | - EUR | 0.0% |
| 2023 Q2 | 2.48 Million EUR | 0.0% |
| 2023 Q4 | 2.03 Million EUR | 0.0% |
| 2023 Q3 | 2.03 Million EUR | -18.0% |
| 2023 FY | 2.03 Million EUR | -25.86% |
| 2023 Q1 | - EUR | -100.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q4 | 2.74 Million EUR | 0.0% |
| 2022 Q2 | 2.76 Million EUR | 0.0% |
| 2022 FY | 2.74 Million EUR | -12.44% |
| 2022 Q3 | 2.74 Million EUR | -0.51% |
| 2021 Q4 | 3.13 Million EUR | 0.0% |
| 2021 Q3 | 3.13 Million EUR | -5.4% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q2 | 3.31 Million EUR | 0.0% |
| 2021 FY | 3.13 Million EUR | -21.44% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 3.99 Million EUR | 0.0% |
| 2020 Q2 | 4.09 Million EUR | 0.0% |
| 2020 FY | 3.99 Million EUR | -6.86% |
| 2020 Q3 | 3.99 Million EUR | -2.54% |
| 2019 Q2 | 4.75 Million EUR | -3.82% |
| 2019 FY | 4.28 Million EUR | 418.26% |
| 2019 Q4 | 4.28 Million EUR | -18.59% |
| 2019 Q3 | 5.26 Million EUR | 10.73% |
| 2019 Q1 | 4.94 Million EUR | 497.82% |
| 2018 FY | 827 Thousand EUR | -21.16% |
| 2018 Q4 | 827 Thousand EUR | 14.07% |
| 2018 Q1 | 835 Thousand EUR | -20.4% |
| 2018 Q2 | 762 Thousand EUR | -8.74% |
| 2018 Q3 | 725 Thousand EUR | -4.86% |
| 2017 Q3 | 652 Thousand EUR | -11.77% |
| 2017 Q1 | 284 Thousand EUR | -16.22% |
| 2017 FY | 1.04 Million EUR | 209.44% |
| 2017 Q4 | 1.04 Million EUR | 60.89% |
| 2017 Q2 | 739 Thousand EUR | 160.21% |
| 2016 Q4 | 339 Thousand EUR | -13.52% |
| 2016 FY | 339 Thousand EUR | -38.14% |
| 2016 Q3 | 392 Thousand EUR | -11.91% |
| 2016 Q2 | 445 Thousand EUR | -10.46% |
| 2016 Q1 | 497 Thousand EUR | -9.31% |
| 2015 Q1 | 11.81 Million EUR | 11.46% |
| 2015 Q2 | 648 Thousand EUR | -94.51% |
| 2015 FY | 548 Thousand EUR | -94.83% |
| 2015 Q4 | 548 Thousand EUR | -8.36% |
| 2015 Q3 | 598 Thousand EUR | -7.72% |
| 2014 Q4 | 10.59 Million EUR | 0.0% |
| 2014 Q2 | 9.87 Million EUR | -1.71% |
| 2014 FY | 10.59 Million EUR | 2.33% |
| 2014 Q1 | 10.05 Million EUR | -2.95% |
| 2014 Q3 | - EUR | -100.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 FY | 10.35 Million EUR | 0.0% |
| 2013 Q3 | 10.85 Million EUR | -5.73% |
| 2013 Q2 | 11.51 Million EUR | 0.0% |
| 2013 Q4 | 10.35 Million EUR | -4.62% |
| 2012 Q3 | - EUR | 0.0% |
| 2012 Q1 | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| 2012 Q4 | - EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2011 Q1 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q3 | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q3 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 Q1 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioNTech SE | 191 Million EUR | 98.934% |
| CureVac N.V. | 36.81 Million EUR | 94.47% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 99.46% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 99.46% |
| BRAIN Biotech AG | 25.19 Million EUR | 91.918% |
| Formycon AG | 7.81 Million EUR | 73.948% |
| Heidelberg Pharma AG | 70.4 Thousand EUR | -2791.758% |